Bibliografía

 sobre  roflumilast  

ROFLUMILAST

1. Pulm Pharmacol Ther. 2011 Jan 19. [Epub ahead of print]

PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease.
Diamant Z, Spina D.

2. Br J Pharmacol. 2011 Jan 14. [Epub ahead of print]

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic
obstructive pulmonary disease.
Rabe KF.

3. Drugs Today (Barc). 2010 Nov;46(11):823-31.

Roflumilast for COPD.
Izquierdo JL, Aparicio J.

4. Prim Care Respir J. 2010 Dec;19(4):342-51.

The use of roflumilast in COPD: a primary care perspective.
Price D, Chisholm A, Ryan D, Crockett A, Jones R.

5. Clin Respir J. 2010 Oct;4(4):197-2010

Roflumilast: clinical benefit in patients suffering from COPD.
Ulrik CS, Calverley PM.

6. Nat Rev Drug Discov. 2010 Oct;9(10):761-2.

Roflumilast.
Fabbri LM, Beghé B, Yasothan U, Kirkpatrick P.

7. Drug Des Devel Ther. 2010 Jul 21;4:147-58.

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Giembycz MA, Field SK.

8. Drugs. 2010 Aug 20;70(12):1615-27. doi: 10.2165/11205930-000000000-00000.

Roflumilast: in chronic obstructive pulmonary disease.
Sanford M.

9. Expert Rev Respir Med. 2010 Oct;4(5):543-55.

Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF.

10. COPD. 2010 Apr;7(2):141-53.

Treatment of chronic obstructive pulmonary disease with roflumilast, a new
phosphodiesterase 4 inhibitor.
Gross NJ, Giembycz MA, Rennard SI.

11. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. Epub 2010 Apr 7.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4
inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.

12. Expert Opin Pharmacother. 2010 Feb;11(3):441-9.

Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
Cazzola M, Picciolo S, Matera MG.

  1  
13. Lancet. 2009 Aug 29;374(9691):695-703.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated
with longacting bronchodilators: two randomised clinical trials.
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF;
M2-127 and M2-128 study groups.

14. Lancet. 2009 Aug 29;374(9691):685-94.

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised
clinical trials.
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-
125 study groups.

15. Expert Rev Respir Med. 2008 Oct;2(5):539-49.

Roflumilast: systemic therapy for chronic obstructive pulmonary disease.
McIvor RA.

16. Expert Opin Investig Drugs. 2008 May;17(5):811-8.

Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of
COPD and asthma.
Field SK.

17. Int J Chron Obstruct Pulmon Dis. 2007;2(2):121-9.

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on
roflumilast.
Boswell-Smith V, Spina D.

18. Expert Rev Clin Immunol. 2007 Jul;3(4):469-76.

Treatment of obstructive airway diseases with roflumilast, a novel
phosphodiesterase 4 inhibitor.
Bardin PG.

19. Respiration. 2007;74(4):411-7. Epub 2006 Sep 5.

Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness
after allergen challenge.
Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG.

20 Expert Opin Investig Drugs. 2006 Sep;15(9):1105-13.

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory
disease.
Boswell-Smith V, Page CP.

21. Ann Pharmacother. 2006 Jun;40(6):1096-104. Epub 2006 May 30.

The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB, Gagnon JM.

22. Ann Allergy Asthma Immunol. 2006 May;96(5):679-86.

Efficacy and safety of roflumilast in the treatment of asthma.
Bateman ED, Izquierdo JL, Harnest U, Hofbauer P, Magyar P, Schmid-Wirlitsch C, Leichtl S,
Bredenbröker D.

23. Curr Opin Investig Drugs. 2006 May;7(5):412-7.

Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA.

  2  
24. Drugs Today (Barc). 2005 Oct;41(10):667-75.
Roflumilast: a selective phosphodiesterase 4 inhibitor.
Christie P.

25. Issues Emerg Health Technol. 2005 Oct;(74):1-4.

Roflumilast for asthma and chronic obstructive pulmonary disease.
Cowan C.

  3